Showing 661-670 of 2293 results for "".
- Ofatumumab Reduced Annualized Relapse Rate in MS in Phase 3 Clinical Trialshttps://practicalneurology.com/news/ofatumumab-reduced-annualized-relapse-rate-in-ms-in-phase-3-clinical-trials/2469346/As published in The New England Journal of Medicine (NEJM), the ASCLEPIOS 1 (NCT02792218) and 2 (
- DHODH Inhibitor Reduces Lesions Significantly in Relapsing-Remitting MShttps://practicalneurology.com/news/dhodh-inhibitor-reduces-lesions-significantly-in-relapsing-remitting-ms/2469343/A phase 2 clinical trial (NCT03846219) of a selective oral Dihydroorotate dehydrogenase (DHODH) inhibitor (IMU-838; Immunic, New York, NY) provided a significant reduction in lesions in participan
- T-Cell Immunotherapy for Progressive MS Shows Safety and Efficacyhttps://practicalneurology.com/news/t-cell-immunotherapy-for-progressive-ms-shows-safety-and-efficacy/2469276/Data from an ongoing study of an allogeneic EBV T-cell immunotherapy (ATA188; Atara Biotherapeutics, South San Francisco, CA) showed safety and efficacy for the treatment of progressive multiple sclerosis (PMS). Composite scales of clinical outcome and of sustained disability improvement (S
- Data Show Ocrelizumab Reduces Disability Progression and Disease Risk in MShttps://practicalneurology.com/news/data-show-ocrelizumab-reduces-disability-progression-and-disease-risk-in-ms/2469242/Post hoc analysis of data from phase 3 Opera 1 (NCT01247324) and Opera 2 (NCT01298492) studies,
- Alemtuzumab Effective for Treatment of MS Over 8 Years of Follow Uphttps://practicalneurology.com/news/alemtuzumab-effective-for-treatment-of-ms-over-8-years-of-follow-up/2468817/After 8 years of treatment with alemtuzumab (Lemtrada; Sanofi, Bridgewater, NJ), patients treated with 3 or more courses of the drug had an annualized relapse rate (ARR) of 0.18%, 85% of patients have been free of relapses, and 70% of patients had stable or improved scores on the Expanded Disabil
- Data Regarding Novel CD40 Ligand Inhibitor as Potential Treatment for Individuals with Relapsing MS Presented at AAN 2025https://practicalneurology.com/news/data-regarding-novel-cd40-ligand-inhibitor-as-potential-treatment-for-individuals-with-relapsing-ms-presented-at-aan-2025/2474004/Results from an open-label extension (OLE) of a phase 2 clinical trial (NCT04879628) for frexalimab (Sanofi; Bridgewater, NJ), an investigational CD40 ligand inhibitor not associated with lymphocyte depletion being studied as a potential treatment for people with relapsing multiple sclerosis, wer
- Switching to SC Kesimpta from IVAnti-CD20 Therapies is Safe, Effective Across Diverse Individuals with Relapsing MShttps://practicalneurology.com/news/Switching-SC-Kesimpta-IVAnti-CD20-Therapies-Safe-Effective-Across-Diverse-Individuals-Relapsing-MS/2471739/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that treatment with Kesimpta (ofatumumab; Novartis, Cambridge, MA) maintained efficacy across ethnic and racial groups in individuals with relapsing multiple sclero
- Switching to SC Kesimpta from IV Anti-CD20 Therapies is Safe, Effective Across Diverse Individuals with Relapsing MShttps://practicalneurology.com/news/kesimpta-maintains-efficacy-across-race-and-ethnic-groups-in-relapsing-ms-patients-transitioning-from-intravenous-anti-cd20-therapies/2473797/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that treatment with Kesimpta (ofatumumab; Novartis, Cambridge, MA) maintained efficacy across ethnic and racial groups in individuals with relapsing multiple sclero
- Washout Period Following Dimethyl Fumarate Treatment Cessation Associated with MS Disease Activity and Relapsehttps://practicalneurology.com/news/washout-period-duration-following-dimethyl-fumarate-treatment-cessation-associated-with-ms-disease-activity-and-relapse/2470484/According to results presented at the 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), disease activity was significantly associated with the duration of the interval between cessation of dimethyl fumarate (DMF) treatment and the initiation of an alternative disease-mod
- One-Year Data from OCARINA II Show Suppression of Relapses/Lesions in MS with Subcutaneous Ocrevus Treatmenthttps://practicalneurology.com/news/one-year-data-from-ocarina-ii-show-suppression-of-relapseslesions-in-ms-with-subcutaneous-ocrevus-treatment/2470456/Data from the OCARINA II study (NCT05232825) presented at the American Academy of Neurology (AAN) 2024 Annual Meeting showed that subcutaneous (SC) injection of Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) resulted in near-complete suppression of clinical relapses and brain lesions i